FR23C1025I1 - METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY - Google Patents
METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPYInfo
- Publication number
- FR23C1025I1 FR23C1025I1 FR23C1025C FR23C1025C FR23C1025I1 FR 23C1025 I1 FR23C1025 I1 FR 23C1025I1 FR 23C1025 C FR23C1025 C FR 23C1025C FR 23C1025 C FR23C1025 C FR 23C1025C FR 23C1025 I1 FR23C1025 I1 FR 23C1025I1
- Authority
- FR
- France
- Prior art keywords
- methods
- cell therapy
- barr virus
- associated lymphoproliferative
- lymphoproliferative syndromes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002659 cell therapy Methods 0.000 title 1
- 230000001589 lymphoproliferative effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160549P | 2015-05-12 | 2015-05-12 | |
| PCT/US2016/031784 WO2016183153A1 (en) | 2015-05-12 | 2016-05-11 | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR23C1025I1 true FR23C1025I1 (en) | 2023-07-21 |
Family
ID=56027234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR23C1025C Active FR23C1025I1 (en) | 2015-05-12 | 2023-06-14 | METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10568908B2 (en) |
| EP (1) | EP3294304B1 (en) |
| JP (2) | JP7284556B2 (en) |
| CN (1) | CN107835690A (en) |
| AR (1) | AR104598A1 (en) |
| AU (1) | AU2016262484B2 (en) |
| BR (1) | BR112017024431B1 (en) |
| CA (1) | CA2984178C (en) |
| CL (1) | CL2017002846A1 (en) |
| FR (1) | FR23C1025I1 (en) |
| HK (1) | HK1244697A1 (en) |
| IL (1) | IL255581B (en) |
| MX (1) | MX2017014257A (en) |
| NZ (1) | NZ736675A (en) |
| PH (1) | PH12017501993A1 (en) |
| RU (1) | RU2720245C2 (en) |
| WO (1) | WO2016183153A1 (en) |
| ZA (1) | ZA201707335B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3465203A4 (en) | 2016-05-25 | 2020-07-29 | The Council of the Queensland Institute of Medical Research | Methods of immunotherapy |
| EP3700553A1 (en) | 2017-10-23 | 2020-09-02 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| CN108220237B (en) * | 2017-12-20 | 2020-11-06 | 中国科学院遗传与发育生物学研究所 | Human NK/T cell line |
| WO2019136379A1 (en) * | 2018-01-08 | 2019-07-11 | Atara Biotherapeutics, Inc. | Systems and methods for distributing cell therapies |
| WO2019178170A1 (en) | 2018-03-14 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
| AU2020371562A1 (en) * | 2019-10-23 | 2022-06-09 | The Council Of The Queensland Institute Of Medical Research | Adoptive immunotherapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| JP4824389B2 (en) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof |
| WO2010049935A1 (en) | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| AU2011295845B2 (en) | 2010-09-01 | 2016-09-22 | Baylor College Of Medicine | EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC) |
| ES2607148T3 (en) * | 2012-05-08 | 2017-03-29 | The Johns Hopkins University | Methods and compositions for infusion of selected populations of allogeneic lymphocytes with transient arrest to treat cancer |
| CA2889064A1 (en) * | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| JP2016539929A (en) * | 2013-10-25 | 2016-12-22 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | Polyclonal γδ T cells for immunotherapy |
| PE20171135A1 (en) * | 2014-11-05 | 2017-08-09 | Memorial Sloan Kettering Cancer Center | METHODS TO SELECT A LINE OF T-CELLS AND DONOR THEM FOR ADOPTIVE CELLULAR THERAPY |
| WO2017003763A1 (en) * | 2015-06-27 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Methods of treating glioblastoma multiforme by t cell therapy |
-
2016
- 2016-05-11 CN CN201680039509.4A patent/CN107835690A/en active Pending
- 2016-05-11 MX MX2017014257A patent/MX2017014257A/en unknown
- 2016-05-11 US US15/572,557 patent/US10568908B2/en active Active
- 2016-05-11 AR ARP160101364A patent/AR104598A1/en unknown
- 2016-05-11 JP JP2017559029A patent/JP7284556B2/en active Active
- 2016-05-11 EP EP16724230.4A patent/EP3294304B1/en active Active
- 2016-05-11 AU AU2016262484A patent/AU2016262484B2/en active Active
- 2016-05-11 NZ NZ736675A patent/NZ736675A/en unknown
- 2016-05-11 CA CA2984178A patent/CA2984178C/en active Active
- 2016-05-11 RU RU2017143151A patent/RU2720245C2/en active
- 2016-05-11 WO PCT/US2016/031784 patent/WO2016183153A1/en active Application Filing
- 2016-05-11 BR BR112017024431-4A patent/BR112017024431B1/en active IP Right Grant
-
2017
- 2017-10-27 ZA ZA2017/07335A patent/ZA201707335B/en unknown
- 2017-11-02 PH PH12017501993A patent/PH12017501993A1/en unknown
- 2017-11-09 IL IL255581A patent/IL255581B/en active IP Right Grant
- 2017-11-10 CL CL2017002846A patent/CL2017002846A1/en unknown
-
2018
- 2018-03-28 HK HK18104239.3A patent/HK1244697A1/en unknown
-
2021
- 2021-04-19 JP JP2021070234A patent/JP2021119154A/en active Pending
-
2023
- 2023-06-14 FR FR23C1025C patent/FR23C1025I1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016262484A1 (en) | 2018-01-04 |
| IL255581A (en) | 2018-01-31 |
| MX2017014257A (en) | 2018-04-20 |
| RU2017143151A3 (en) | 2019-10-29 |
| CN107835690A (en) | 2018-03-23 |
| JP2018520095A (en) | 2018-07-26 |
| CL2017002846A1 (en) | 2018-05-25 |
| KR20180003575A (en) | 2018-01-09 |
| IL255581B (en) | 2021-03-25 |
| AU2016262484B2 (en) | 2021-10-21 |
| RU2017143151A (en) | 2019-06-13 |
| RU2720245C2 (en) | 2020-04-28 |
| PH12017501993A1 (en) | 2018-03-26 |
| JP7284556B2 (en) | 2023-05-31 |
| CA2984178A1 (en) | 2016-11-17 |
| EP3294304B1 (en) | 2020-01-29 |
| BR112017024431A2 (en) | 2018-07-24 |
| AR104598A1 (en) | 2017-08-02 |
| WO2016183153A1 (en) | 2016-11-17 |
| CA2984178C (en) | 2023-10-31 |
| EP3294304A1 (en) | 2018-03-21 |
| HK1244697A1 (en) | 2018-08-17 |
| ZA201707335B (en) | 2021-02-24 |
| JP2021119154A (en) | 2021-08-12 |
| US20180125891A1 (en) | 2018-05-10 |
| NZ736675A (en) | 2023-03-31 |
| BR112017024431B1 (en) | 2021-10-13 |
| US10568908B2 (en) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1025I1 (en) | METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY | |
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| DK3597646T3 (en) | THERAPEUTIC COMPOUNDS SUITABLE FOR THE PROHYPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION | |
| HRP20190352T1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| ZA201900156B (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| MA40867A (en) | METHODS FOR THE TREATMENT OF FILOVIRIDAE VIRAL INFECTIONS | |
| HK1223931A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| MA50264A (en) | METHODS OF TREATING HEPATITIS B INFECTIONS | |
| DK3294740T3 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection | |
| MA43925A (en) | Hepatitis B virus treatment process | |
| DK3137078T3 (en) | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | |
| DK3370723T3 (en) | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | |
| DK3352857T3 (en) | SYD985 TREATMENT OF T-DM1 REFRACTORY CANCER PATIENTS | |
| MA46967A (en) | METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS | |
| DK3471732T3 (en) | LIPOSOMES FOR THE TREATMENT OF VIRUS INFECTIONS | |
| IL288713A (en) | Methods to treat viral infections | |
| ZA201804025B (en) | Inactivation of viruses by delipidation | |
| EA201791356A1 (en) | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | |
| ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |